One Stop Shop For Reports One Stop Shop For Reports
  • Reports
  • Press Release
  • Statistics
  • About Us
  • [email protected]
  • +1 718 874 1545 (International)
  • +91 78878 22626 (Asia)

More Results

One Stop Shop For Reports One Stop Shop For Reports
  • Reports
  • Press Release
  • Statistics
  • About Us
Home ➤ Press Releases ➤ AEON Biopharma Reports Equity Inducement Awards Under NYSE American Section 711
AEON Biopharma Reports Equity Inducement Awards Under NYSE American Section 711
AEON Biopharma Reports Equity Inducement Awards Under NYSE American Section 711
  • Home ➤ Press Releases ➤ AEON Biopharma Reports Equity Inducement Awards Under NYSE American Section 711

AEON Biopharma Reports Equity Inducement Awards Under NYSE American Section 711

IRVINE, CA — December 19, 2025 — AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) for accelerated and full-label U.S. market entry, today announced that its Board of Directors approved inducement equity grants in December 2025 totaling 392,158 restricted stock units (RSUs) to newly hired non-executive employees.

The equity awards were granted under the Company’s 2025 Inducement Incentive Plan on December 11, 2025, with vesting commencement dates in December 2025.

Terms of the Award

  • Vesting Schedule: The RSUs will vest over a four-year period, with 25% vesting on each annual anniversary of the applicable vesting commencement date, subject to continued employment.

  • Governance & Plan Terms: The grants are subject to the terms and conditions of AEON’s 2025 Inducement Incentive Plan and individual RSU grant agreements.

  • Regulatory Compliance: The equity grants were awarded as a material inducement to new employees entering into employment with AEON in accordance with Section 711 of the NYSE American LLC Company Guide.

About the U.S. Biosimilar Pathway

The U.S. Food and Drug Administration (“FDA”) regulates biosimilars under the Public Health Service Act’s 351(k) pathway, which require developers to demonstrate that a proposed product is highly similar to an approved reference biologic with no clinically meaningful differences in safety, purity, or potency. Analytical similarity is the scientific foundation of this process, representing the most critical and data-intensive phase of development. Once analytical comparability across key quality attributes is established, subsequent FDA interactions focus on confirming whether any residual uncertainty requires limited clinical evaluation.

About AEON Biopharma

AEON Biopharma is a biopharmaceutical company seeking accelerated and full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. The Company’s lead asset is ABP-450 for debilitating medical conditions. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau®. ABP-450 is manufactured by Daewoong Pharmaceutical in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada, and European Medicines Agency. The product is approved as a biosimilar in India, Mexico, and the Philippines. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com.

Contacts

Investor Contact:
Laurence Watts
New Street Investor Relations
+1 619 916 7620
[email protected]

Related Press Releases

  • TechnoVision: Top 5 Tech Trends to Watch in 2027 By Capgemini
  • AGC Biologics Welcomes Multiple Cell Therapy Projects at Its New Yokohama Facility
  • BlackLine Launches Availability on Anthropic’s Claude Marketplace
  • Mobilicom Announces Participation in Upcoming Industry and Investor Conferences
  • AI Errors Strain Business Finances and Delay Projects Worldwide
  • Neurosterix, an Addex Spin-Out, Closes $105 Million Series B Financing
Latest report from the featured industries
  • Advanced Materials
    Optical Coating Market
    Spray Drying Equipment Market
    Metal Roofing Market
    Stone And Tile Adhesives And Sealants Market
    Armor Materials Market
    PTFE Hoses Market
    Roofing Materials Market
    Acrylic Foam Tape Market
    Oil Shale Market
    Pine-Derived Chemicals Market
  • Aerospace and Defence
    Satellite Launch Systems Market
    Satellite Communication In The Defense Sector Market
    Lyocell Fabric Market
    Bullet Proof Jacket Market
    Rescue Pole Market
    Police Baton Market
    Drone Battery Market
    Gunshot Detection System Market
    Military Electro-optical And Infrared Systems Market
    Multirotor Drone Market
  • Agriculture & Agri Products
    Mooring Systems Market
    Oilseed Processing Market
    Cut Flowers Market
    Cotton Processing Market
    Farm Equipment Rental Market
    Agricultural Variable Rate Technology Market
    Indoor Farming Technology Market
    Essential Oils And Plant Extract For Livestock Market
    Food Vacuum Machine Market
    Ornamental Horticulture Market
  • Apparel | Fashion & Accessories
    3D Printed Jewelry Market
    Cotton (Linter) Pulp Market
    Snow Boots Market
    Merchandise Designing Market
    Volleyball Shoes Market
    Smart Clothing Market
    Workwear Market
    Down Jacket Market 
    Decorated Apparel Market
    Dancewear Market
  • Artificial Intelligence
    AI-Based Defect Detection Software Market
    AI Vision For Manufacturing Market
    AI Training Data Lineage Software Market
    AI Portfolio And Pipeline Management Software Market
    AI In Testing Inspection And Certification Market
    Agentic AI Market
    AI In Telecommunication Market
    AI In Materials Science Market
    AI Data Labeling Market
    AI Data Center Power Consumption Market
✖
Request a Sample Report
We'll get back to you as quickly as possible
CAPTCHA Code

✖
Request a Sample Report
We'll get back to you as quickly as possible
CAPTCHA Code

  • location_on420 Lexington Avenue, Suite 300 New York City, NY 10170,
    United States
  • phone+1 718 874 1545 (International)
  • phone+91 78878 22626 (Asia)
  • email[email protected]
  • Facebook Logo
  • Twitter Logo
  • LinkedIn Logo
Find Help
  • Contact Us
  • How to Order
Legal
  • Privacy Policy
  • Refund Policy
  • Frequently Asked Questions
  • Terms and Conditions
Explore
  • About Us
  • Our Clients
  • Media Mentions
  • Infographics
  • Statistics and Facts
  • Research Methodology
  • Why Choose Us?
Secured Payment Options
Secured Payment Options

© 2026 Market.Us. All Rights Reserved.